Entries by Steve

United States Hidradenitis Suppurativa Market, 2014-2019 & 2024 – Pipeline, Epidemiology, Market Valuations, Drugs (Sales & Market Share), and Competitive Landscape

DUBLIN–(BUSINESS WIRE)– The “US Hidradenitis Suppurativa Market and Competitive Landscape – 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights into Hidradenitis Suppurativa pipeline products, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa market valuations and forecast, Hidradenitis Suppurativa drugs sales and competitive landscape in the US. The research is classified into seven sections […]

Analysts See $-0.55 EPS for InflaRx N.V. (IFRX); Anchor Capital Advisors Has Lowered By $1.58 Million Its Boston Scientific (BSX) Holding

Anchor Capital Advisors Llc decreased Boston Scientific Corp (BSX) stake by 3.46% reported in 2019Q1 SEC filing. Anchor Capital Advisors Llc sold 41,534 shares as Boston Scientific Corp (BSX)’s stock declined 6.39%. The Anchor Capital Advisors Llc holds 1.16M shares with $44.48 million value, down from 1.20M last quarter. Boston Scientific Corp now has $59.36 […]

Safe-t Group LTD. – American Depositary Share (NASDAQ:SFET)’s Trend Up, Especially After Decreased Shorts

The stock of Safe-t Group LTD. – American Depositary Share (NASDAQ:SFET) registered a decrease of 42.72% in short interest. SFET’s total short interest was 5,900 shares in July as published by FINRA. Its down 42.72% from 10,300 shares, reported previously. With 61,800 shares average volume, it will take short sellers 0 days to cover their […]

Hidradenitis Suppurativa Treatment Market Size, Industry Status and Growth opportunities for Leading Players| GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer

Los Angeles, United State, July 19, 2019, – The latest report published by QY Research presents a thorough analysis of the global Hidradenitis Suppurativa Treatment market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it […]

Inflarx pushes past the red flags to claim a win

Anyone with more than a fleeting experience of biotech investment should be familiar with the practice of post-hoc data dredging of a failed clinical trial to find hints of activity. Inflarx’s claim yesterday that its clearly negative study of IFX-1 in hidradenitis suppurativa did, after all, show robust efficacy is a particularly egregious example of […]

06-2019-InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa

IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HS  IFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety profile with low anti-drug antibody rates  Open-label extension study is ongoing, InflaRx plans end of Phase II regulatory discussions after completion of SHINE trial  Conference call […]

ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.21; Erytech Pharma S.A. – American Depositary Shares (ERYP) Shorts Decreased By 47.27%

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.21 EPS on August, 8.They anticipate $0.07 EPS change or 50.00% from last quarter’s $-0.14 EPS. After having $-0.23 EPS previously, ChemoCentryx, Inc.’s analysts see -8.70% EPS growth. The stock increased 1.97% or $0.16 during the last trading session, reaching $8.27. About 195,998 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) […]